Afinitor Approval Expanded to Include Benign Kidney Tumors
Growths caused by rare genetic disease
FRIDAY, April 27 (HealthDay News) -- Afinitor (everolimus) is the first drug to be approved by the U.S. Food and Drug Administration to treat benign kidney tumors among people with tuberous sclerosis complex (TSC), the agency said in a news release.
TSC causes non-cancerous tumors of the brain, kidney, and other organs, the FDA said. The disease affects up to 40,000 people in the United States, and as many as 80 percent develop kidney problems.
Afinitor helps suppress these tumors by blocking mTOR kinase, the FDA said.
The drug's safety and effectiveness were clinically evaluated among 118 people with TSC. The most common side effects were inflamed or sore mouth, nausea and vomiting, acne, eczema, cough, headache, diarrhea, abdominal pain, joint pain, and swelling of the legs or arms. Some 15 percent of females who took Afinitor missed at least one menstrual period.
Afinitor was first approved by the FDA in 2009 to treat kidney tumors that weren't treated successfully with other drugs.
Afinitor is produced by Novartis, based in East Hanover, N.J.
To learn more about this drug, visit the U.S. National Cancer Institute.